Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 16, 2024 11:15 ET | Source: NeOnc Technologies Holdings, Inc.

NeOnc Technologies Receives FDA Approval to Expand NEO100-01™ Phase 2a Clinical Trial to Include Patients with Recurrent Grade III Astrocytoma Brain Tumors Exhibiting IDH1 Mutation

FDA approval reflects positive results from Phase I and preliminary results from Phase IIa study currently underway that demonstrate increased survivability rates in patients with the IDH1...
June 26, 2024 16:39 ET | Source: NeOnc Technologies Holdings, Inc.

NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status

New investment and debt conversion by new and existing investors sets company’s post-money valuation at approximately $220 million, up 214% from previous funding round.Financing supports further...
April 04, 2023 14:00 ET | Source: NeOnc Technologies Holdings, Inc.

NeOnc Technologies CEO, Thomas Chen, MD, Ph.D., Awarded American Health Council’s ‘Best in Medicine’

LOS ANGELES and CHICAGO and LONDON, April 04, 2023 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings Inc., a clinical stage medical biotechnology company, announced that its CEO, Thomas Chen, MD,...
March 06, 2023 08:00 ET | Source: NeOnc Technologies Holdings, Inc.

NeOnc Technologies Engages Anova Enterprises to Pursue Pediatric Brain Tumor Indication and FDA Fast-Track Status for NEO100®

Anova Enterprises, a clinical research organization, to prepare FDA Fast Track and Rare Pediatric Designation application for NEO100® for Pediatric High-Grade Gliomas (pHGGS) brain tumors.AnovaOS™...
August 24, 2022 08:30 ET | Source: Future Market Insights Global and Consulting Pvt. Ltd.

Brain Tumor Treatment Market is expected to accumulate a Value of US$ 5,904.82 Million by registering a CAGR of 7.2% | Future Market Insights, Inc.

NEWARK, Del, Aug. 24, 2022 (GLOBE NEWSWIRE) -- The global brain tumor treatment market is anticipated to showcase an opulent growth opportunity over the estimation period from 2022 to 2032 with a...
July 15, 2022 08:30 ET | Source: The Insight Partners

Brain Cancer Diagnostics Market Revenue to Cross $7.37 Bn Globally, by 2028 at 28.5.% CAGR - Exclusive Report by The Insight Partners

New York, July 15, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Brain Cancer Diagnostic Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by...
December 04, 2019 09:35 ET | Source: Lixte Biotechnology Holdings, Inc.

First Two Patients Enrolled in National Cancer Institute Trial of the Ability of Lixte Biotechnology’s LB-100 to Enter Recurrent Malignant Brain Tumors

EAST SETAUKET, NY, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that the National Cancer Institute (NCI) has enrolled the first two patients of a...